61 results on '"Springer, Simeon"'
Search Results
2. Data from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
3. Supplementary Figure 4 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
4. Supplementary Figure 1 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
5. Data from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
6. Supplementary Figure 5 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
7. Supplementary Table 2 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
8. Supplementary Figure 5 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
9. Supplementary Figure 4 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
10. Supplementary Table 1 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
11. Supplementary Figure 3 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
12. Supplementary Table 2 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
13. Supplementary Figure 3 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
14. Supplementary Figure 2 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
15. Supplementary Figure 1 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
16. Supplementary Table 1 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
17. Supplementary Methods, Figure Legends from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
18. Supplementary Figure 2 from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
19. Supplementary Methods, Figure Legends from Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
20. Data from TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine
21. Data from TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine
22. Supplementary Table 1 from TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine
23. Supplementary Table 1 from TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine
24. Correction to: Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology
25. Global genome analysis reveals a vast and dynamic anellovirus landscape within the human virome
26. Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations
27. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma
28. Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology
29. A multimodality test to guide the management of patients with a pancreatic cyst
30. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations
31. Correction: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy
32. Evaluation of Liquid From the Papanicolaou Test and Other Liquid Biopsies for the Detection of Endometrial and Ovarian Cancers
33. MP65-13 UROSEEK: A NOVEL NON-INVASIVE MOLECULAR METHOD FOR EARLY DETECTION OF BLADDER CANCER
34. MP65-14 UROSEEK: A NOVEL NON-INVASIVE MOLECULAR ASSAY FOR SURVEILLANCE OF BLADDER CANCER
35. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers
36. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy
37. Author response: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy
38. Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs)
39. Non-invasive detection of bladder cancer through the analysis of driver gene mutations and aneuploidy
40. Non-invasive detection of upper tract urothelial carcinomas through the analysis of driver gene mutations and aneuploidy in urine
41. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder
42. Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations
43. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma
44. Diagnostic potential of tumor DNA from ovarian cyst fluid
45. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
46. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder
47. A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts
48. Author response: Diagnostic potential of tumor DNA from ovarian cyst fluid
49. The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.
50. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.